Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)	1 Months Ended		3 Months Ended		6 Months Ended	12 Months Ended
	Feb. 29, 2016 USD ($)	Aug. 31, 2015 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015	Dec. 31, 2015 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2014 USD ($)	Jun. 30, 2014 USD ($)
Scenario, Forecast [Member]
Gross Proceeds from Financing Transaction	$ 15,000,000
Debt Issuance Cost					$ 770,000	$ 0
Cash and Cash Equivalents, at Carrying Value			$ 2,942,000		2,942,000	3,357,000	$ 8,357,000	$ 14,811,000
Working Capital			3,341,000		3,341,000
Retained Earnings (Accumulated Deficit)			(141,695,000)		(141,695,000)	$ (137,674,000)
Gross Proceeds from Convertible Debt		$ 5,500,000
Potential Proceed from Issuance of Convertible Debt			9,500,000
Approval for Grant in Amount for Clinical Trial		$ 10,000,000	$ 10,000,000		$ 10,000,000
Maximum Period Of Agreement				21 years
Number of Reportable Segments					1